UK Markets close in 5 hrs 50 mins

Cosmo Pharmaceuticals N.V. (0RGI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
67.95+2.23 (+3.40%)
As of 05:47PM GMT. Market open.
Full screen
Previous close65.71
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume5,244
Avg. volumeN/A
Market cap1.001B
Beta (5Y monthly)1.01
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi® in Southeast Asia

    Cosmo Pharmaceuticals N.V. / Key word(s): Agreement21-Dec-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland & Singapore – 21 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyphens Pharma International Limited (SGX: 1J5) (“Hyphens”) today announced the signing of License and Supply Agreements for Winlevi® (clasco

  • EQS Group

    Cosmo announces successful Phase III clinical trial of Lumeblue™ in China

    Cosmo Pharmaceuticals N.V. / Key word(s): Study resultsCosmo announces successful Phase III clinical trial of Lumeblue™ in China 14.12.2022 / 06:00 GMT/BST Dublin, Ireland – 14 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful phase III clinical trial of Lumeblue™ in China, sponsored by its partner China Medical System Holdings Limited (CMS) (867.HK). In the trial, Lumeblue™ was compared to placebo in white light colonoscopy with the purpo

  • EQS Group

    Cosmo announces FDA grants orphan-drug designation ofrifamycin for treatment of pouchitis

    Cosmo Pharmaceuticals N.V. / Key word(s): Regulatory ApprovalCosmo announces FDA grants orphan-drug designation ofrifamycin for treatment of pouchitis 20.10.2022 / 06:00 GMT/BSTDublin, Ireland – 20 October 2022. Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announces that the FDA has granted the orphan-drug designation request of rifamycin for treatment of pouchitis.Patients with ulcerative colitis (UC) may require removal of their colon and rectum (proctocolectomy), and the surgi